PTN — PALATIN TECHNOLOGIES, INC. COMMON STOCK (Healthcare >> Biotechnology)
PTN FAQ
What is PTN's P/E ratio?
PALATIN TECHNOLOGIES, INC. COMMON STOCK (PTN) currently trades at a P/E ratio of 5.18.
What is PTN's ROE?
PALATIN TECHNOLOGIES, INC. COMMON STOCK reports a Return on Equity (ROE) of -59.00%.
What is PTN's dividend yield?
PALATIN TECHNOLOGIES, INC. COMMON STOCK offers a dividend yield of 0.00%.
What is PTN's Deepscope Quality Score?
Deepscope rates PTN's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy PTN?
Deepscope's AI Timing Score for PTN is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does PTN belong to?
PALATIN TECHNOLOGIES, INC. COMMON STOCK is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 12.50
Price
-1.11
(-8.12%)
Day Change
|
|
|---|
PTN Chất lượng tổng thể của cố phiếu Không tốt ( Chất lượng = 31) và Thời điểm mua ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
Tỷ lệ ROE tương đối thấp
Tỷ lệ ROA tương đối thấp
Tăng trưởng ROE là âm trong năm ngoái.
ROE đang giảm đáng kể
ROA quá thấp so với ROE
Tăng trưởng ROA dưới mức tiêu chí của chúng tôi trong năm vừa qua
Biên lợi nhuận ròng tương đối thấp.
Tốc độ tăng trưởng biên lợi nhuận ròng dưới mức tiêu chí của chúng tôi
Lịch sử Biên lợi nhuận ròng tương đối thấp.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
Chi tiết hơn, sẽ thấy rằng các yếu tố chất lượng Không tốt lắm , Sức khỏe tài chính Không tốt , và khả năng kiếm lợi nhuận Không tốt lắm , ...
| Yếu tố Chất lượng |
|
54% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 95 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 12.50 |
| PBV / Sector |
2.29 / 4.90
|
| Earning Per Share | -3.23 |
| PE / Sector |
5.18 / 18.25
GREAT
|
| PEG or PE/Growth / Sector |
0.01 / 0.62
GREAT
|
| Average 1M Daily Value |
0.24 M
GREAT
|
| Average 1W Daily Value |
0.12 M
GREAT
|
| Yếu tố Kỹ thuật |
|
28% |
| Sức khỏe tài chính |
|
45% |
| Khả năng kiếm lợi nhuận |
|
52% |
| Lợi tức cho nhà đầu tư |
|
4% |
| Chi tiết đăng ký |
| Analyze Date | 2026-06-16 09:58:30 |
| Symbol | PTN |
| Name | PALATIN TECHNOLOGIES, INC. COMMON STOCK |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 1.78 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 24.21 / 8,995.97 |
| Tin tức, Dự báo ước tính |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 11 Deer Park Drive, Monmouth Junction, NJ, United States, 08512
Phone: 609 495 2200
Website: https://palatin.com
Sector: Healthcare >> Biotechnology
Description: Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy. The company also develops PL9643 for dry eye disease and anti-inflammatory ocular indications; and oral PL8177 for the treatment inflammatory bowel diseases. Palatin Technologies, Inc. was incorporated in 1986 and is based in Monmouth Junction, New Jersey.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Google